EDINBURGH,
Scotland, Sept. 27, 2023 /PRNewswire/ -- TC BioPharm
(Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:
TCBP) a clinical stage biotechnology company developing
platform allogeneic gamma-delta T cell therapies for cancer, today
announced that CEO, Bryan Kobel will
present at the LD Micro 16th annual Main Event
conference taking place on October 3-5,
2023 at the Luxe Sunset Boulevard Hotel in Los Angeles,
California.
Event: TC BioPharm at the LD Micro
Main Event XVI
Presentation: Tuesday, October 3rd
Time: 10:00 a.m. PT to 1:00 p.m.
ET
For more information on the LD Micro Main Event
or to schedule a one-on-one meeting with TC BioPharm management,
please contact your conference representative or you may also email
your request to ir@tcbiopharm.com
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical
company focused on the discovery, development and commercialization
of gamma-delta T cell therapies for the treatment of cancer with
human efficacy data in acute myeloid leukemia. Gamma-delta T cells
are naturally occurring immune cells that embody properties of both
the innate and adaptive immune systems and can intrinsically
differentiate between healthy and diseased tissue. TC BioPharm uses
an allogeneic approach in both unmodified and CAR modified
gamma-delta T cells to effectively identify, target and eradicate
both liquid and solid tumors in cancer.
TC BioPharm is the leader in developing
gamma-delta T cell therapies, and the first company to conduct
phase II/pivotal clinical studies in oncology. The Company is
conducting two investigator-initiated clinical trials for its
unmodified gamma-delta T cell product line - Phase 2b/3 pivotal trial for OmnImmune® in
treatment of acute myeloid leukemia using the Company's proprietary
allogeneic CryoTC technology to provide frozen product to clinics
worldwide. TC BioPharm also maintains a robust pipeline for future
indications in solid tumors as well as a significant IP/patent
portfolio in the use of CARs with gamma-delta T cells and owns our
manufacturing facility to maintain cost and product quality
controls.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/tc-biopharm-to-present-at-the-ld-micro-main-event-xvi-301939846.html
SOURCE TC BioPharm